Risk factors for esotropia reoperation revealed

Article

Underaction of the lateral rectus muscle could be a risk factor for reoperation of congenital esostropia, claims an investigation in the Journal of Pediatric Ophthalmology and Strabismus.

Underaction of the lateral rectus muscle could be a risk factor for reoperation of congenital esostropia, claims an investigation in the Journal of Pediatric Ophthalmology and Strabismus.

Dr Z. Rajavi et al., Ophthalmic Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran, conducted a study on 157 children with congenital esotropia, who were divided into two groups after a minimum of one operation. The patients included those with a deviation greater than 10 PD or a history of reoperation.

Risk factors such as age at first operation and primary congenital esotropia of less than 30 or more than 50 PD inferior oblique muscle overaction, dissociated vertical deviation, lateral rectus muscle underaction, and A-V pattern with reoperation were recorded.

Reoperation was required in 32.4% of children who presented with residual esotrpia greater than 15 PD after the three-month follow-up. Congenital esotropia greater than 30 PD and lateral rectus muscle underaction of −1 to −2 were statistically different between the two groups and were found to be risk factors of reoperation.

Please click here to view the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.